Loading organizations...
Key people at ClavystBio.
ClavystBio operates as a dedicated life sciences investor and venture builder, translating scientific breakthroughs into tangible health impacts. The company fosters the creation and growth of global life science companies, combining strategic incubation with direct investments. It champions promising scientific endeavors and facilitates novel solution development, accelerating the commercialization of health innovations.
Established in 2021 by Temasek, the Singaporean state-owned investment company, ClavystBio was founded on the insight that accelerating life science commercialization demands comprehensive support beyond capital. The organization emerged to bridge the gap between discovery and patient care, leveraging Temasek's strategic vision to build an integrated ecosystem for life sciences translation.
ClavystBio primarily partners with emerging biotech startups and research institutions aiming to commercialize discoveries, supporting ventures that address significant medical needs. Its long-term vision is to cultivate a dynamic global health innovation landscape, transforming scientific potential into practical, impactful healthcare solutions worldwide.
ClavystBio has 2 tracked investments across 2 companies. The latest tracked deal is $11.0M Seed in Cirrus Therapeutics in October 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Oct 2, 2025 | Cirrus Therapeutics | $11.0M Seed | Clavystbio | Alexandra Cantley, Polaris Partners, Seeds Capital |
| May 1, 2025 | Nuevocor | $45.0M Series B | Elia Stupka, Amanda Gett Chaperot | First Star Ventures, Seventure Partners, Boehringer Ingelheim, EDBI, Seeds Capital |
Key people at ClavystBio.
